CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-06-01 | CHESS ROBERT Director | Exercise or conversion · Stock Option | −5,000 | 10,000 | ||
| 2016-05-17 | Nicholson John SVP & Chief Financial Officer | Sale | −856 | $13.58 | $12K | 77,630 |
| 2016-05-17 | ROBIN HOWARD W President & CEO | Sale | −2,170 | $13.58 | $29K | 16,933 |
| 2016-05-17 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −339 | $13.58 | $5K | 1,021 |
| 2016-05-17 | Gergel Ivan P. SVP & Chief Medical Officer | Sale | −432 | $13.58 | $6K | 1,512 |
| 2016-05-17 | Hora Maninder SVP Pharma Dev & Mfg Ops | Sale | −835 | $13.58 | $11K | 7,135 |
| 2016-05-17 | Labrucherie Gil M SVP & General Counsel | Sale | −836 | $13.58 | $11K | 7,921 |
| 2016-05-17 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −724 | $13.58 | $10K | 6,309 |
| 2016-05-16 | Nicholson John SVP & Chief Financial Officer | Exercise or conversion | +2,167 | $0.00 | $0 | 78,486 |
| 2016-05-16 | Nicholson John SVP & Chief Financial Officer | Returned to the company · Restricted Stock Unit | −2,167 | 21,667 | ||
| 2016-05-16 | ROBIN HOWARD W President & CEO | Exercise or conversion | +5,625 | $0.00 | $1 | 19,103 |
| 2016-05-16 | ROBIN HOWARD W President & CEO | Returned to the company · Restricted Stock Unit | −5,625 | 56,250 | ||
| 2016-05-16 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +875 | $0.00 | $0 | 1,360 |
| 2016-05-16 | Doberstein Stephen K SVP & Chief Scientific Officer | Returned to the company · Restricted Stock Unit | −875 | 8,750 | ||
| 2016-05-16 | Gergel Ivan P. SVP & Chief Medical Officer | Exercise or conversion | +1,250 | $0.00 | $0 | 1,944 |
| 2016-05-16 | Gergel Ivan P. SVP & Chief Medical Officer | Returned to the company · Restricted Stock Unit | −1,250 | 12,500 | ||
| 2016-05-16 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion | +2,167 | $0.00 | $0 | 7,970 |
| 2016-05-16 | Hora Maninder SVP Pharma Dev & Mfg Ops | Returned to the company · Restricted Stock Unit | −2,167 | 21,667 | ||
| 2016-05-16 | Labrucherie Gil M SVP & General Counsel | Exercise or conversion | +2,167 | $0.00 | $0 | 8,757 |
| 2016-05-16 | Labrucherie Gil M SVP & General Counsel | Returned to the company · Restricted Stock Unit | −2,167 | 21,667 |
Page 52 of 55 · 1,088 trades